C4 Therapeutics (CCCC) Accumulated Expenses (2019 - 2026)

C4 Therapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $9.8 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 22.19% year-over-year to $9.8 million in Q1 2026; TTM through Mar 2026 was $9.8 million, a 22.19% decrease from a year earlier, with the FY2025 full-year figure at $13.3 million, down 31.24% from the prior year.
• Accumulated Expenses declined to $9.8 million in Q1 2026 per CCCC's latest filing, from $13.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $20.6 million in Q4 2023 and bottomed at $9.8 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $15.4 million (2024), against an average of $14.9 million.
• Across the five-year window, Accumulated Expenses surged 615.12% in 2022 and tumbled 33.03% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $19.8 million in 2022, then increased by 4.36% to $20.6 million in 2023, then declined by 6.14% to $19.4 million in 2024, then sank by 31.24% to $13.3 million in 2025, then dropped by 26.17% to $9.8 million in 2026.
• Per Business Quant, the three latest CCCC Accumulated Expenses figures stand at $9.8 million (Q1 2026), $13.3 million (Q4 2025), and $11.3 million (Q3 2025).